TriSalus Life Sciences Reports 59% Revenue Growth Driven by TriNav® Infusion System
- TriSalus reports Q4 2024 revenue of $8.3 million, a 44% increase driven by the TriNav® Infusion System.
- Total revenue for 2024 reaches $29.4 million, reflecting a 59% growth, largely due to TriNav® adoption.
- TriSalus projects over 50% revenue growth in 2025, supported by ongoing clinical developments of the TriNav® Infusion System.
TriSalus Life Sciences Reports Strong Growth Driven by TriNav® Infusion System
TriSalus Life Sciences Inc. announces preliminary unaudited financial results for the fourth quarter and full year of 2024, showcasing remarkable growth attributed to its innovative TriNav® Infusion System. The company reports a revenue of approximately $8.3 million for Q4 2024, reflecting a 44% increase compared to the same quarter in 2023. This surge is part of a broader trend, as TriSalus achieves total revenue of around $29.4 million for the entire year, marking a 59% growth over 2023. The significant uptick in revenue highlights the increasing adoption of the TriNav® Infusion System, designed to enhance the delivery of therapeutics in the treatment of cancer, particularly in complex tumor environments.
The performance of TriSalus is particularly noteworthy given the challenges faced by many companies in the biopharmaceutical sector. The company's focus on advancing its infusion technology positions it well within the market, as it addresses a critical need for effective drug delivery systems. TriSalus projects that this growth trajectory will continue into 2025, with an anticipated revenue increase of over 50%. This optimism is supported by ongoing clinical developments and a robust pipeline, suggesting that the TriNav® Infusion System not only meets current market demands but also has the potential for further expansion in therapeutic applications.
Despite facing an operating cash flow loss of about $5.6 million in Q4 2024, TriSalus shows signs of financial improvement, as this represents a notable reduction from the $10.8 million loss recorded in the previous quarter. The company aims to achieve positive EBITDA and cash flow by the latter half of 2025, buoyed by strategic financial maneuvers, including plans to secure an additional $10 million from an existing debt agreement with OrbiMed. This funding is expected to enhance liquidity and support ongoing operations and growth initiatives throughout 2025.
In addition to its financial achievements, TriSalus Life Sciences is preparing for a conference call scheduled for March 27, 2025, at 8:00 a.m. ET. This call will provide an opportunity for stakeholders to delve deeper into the financial results and gain insights into the company’s strategic direction. It is important to note that the preliminary results are subject to revision, emphasizing the need for caution when interpreting the company's financial position.
As TriSalus continues to innovate within the biopharmaceutical landscape, its focus on the TriNav® Infusion System not only positions it for future growth but also reflects an essential shift towards more effective cancer therapies. The company's dedication to enhancing drug delivery systems could lead to significant advancements in treatment options for patients, potentially transforming the standard of care in oncology.